en · de · es · fr · pt
semax-notes.peptides9000.com › Wiki › Background And Development — Research Overview

Background And Development — Research Overview

By Editorial Desk · published 2026-07-13 · last reviewed 2026-08-01 · Wiki

The short version of Semax fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax Structure and Research Background

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Semax at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideAnalog of an ACTH fragment
Amino acid lengthSeven residuesMet-Glu-His-Phe-Pro-Gly-Pro
OriginMoscow, 1980sInstitute of Molecular Genetics
Approved regionsRussia and some neighboring statesNot cleared in Western markets
Common trade namesMultiple national brandsSold as a nasal formulation

Semax Peptide Background and Identity

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Related pages on this site

Semax Origin and Molecular Structure

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Supporting material

In a move seen as marking her return to political life, former prime minister Liz Truss writes an article for The Sunday Telegraph in which she says her economic agenda was never given a "realistic chance". 6 February 2022–2023 National Health Service strikes: Ambulance staff and nurses walk out, with further disruption to follow in the week, in what is expected to be the biggest-ever round of NHS strikes. Foreign Secretary James Cleverly offers his condolences to victims of the 7.8 magnitude Turkey–Syria earthquake and says the UK is deploying emergency response teams, including 76 search and rescue specialists, equipment and rescue dogs. The government issues an urgent warning to British travellers and holidaymakers who may be in or planning to visit the region. 7 February Former Met Police officer David Carrick, one of the UK's most prolific sex offenders, is sentenced at Southwark Crown Court to 36 life sentences with a minimum term of 30 years in prison. Sunak performs a cabinet reshuffle. Greg Hands is named as the new Conservative Party chairman; Grant Shapps becomes the secretary of state for energy, security and net zero in a newly-formed department; Kemi Badenoch is appointed as the first secretary of state at the newly created Department for Business and Trade, with continued responsibility as equalities minister. 8 February Ukraine's President Volodymyr Zelensky addresses a joint session of Parliament during his first visit to the UK since Russia invaded his country. He later visits Buckingham Palace for a meeting with the King.

is the speed of light in vacuum. Typical metals that support surface plasmons are silver and gold, but metals such as copper, titanium or chromium have also been used. When using light to excite SP waves, there are two configurations which are well known. In the Otto configuration, the light illuminates the wall of a glass block, typically a prism, and is totally internally reflected. A thin metal film (for example gold) is positioned close enough to the prism wall so that an evanescent wave can interact with the plasma waves on the surface and hence excite the plasmons. In the Kretschmann configuration (also known as Kretschmann–Raether configuration), the metal film is evaporated onto the glass block. The light again illuminates the glass block, and an evanescent wave penetrates through the metal film. The plasmons are excited at the outer side of the film. This configuration is used in most practical applications.

Dundee becomes the second city in Scotland to introduce a low emission zone. 30 May – Police searching for a father and son missing after hillwalking in Glen Coe confirm they have found two bodies. 31 May – Scotland's UEFA Women's Euro 2025 qualifier match against Israel is delayed after a protestor padlocks himself to the goalposts at Hampden Park. A 24-year-old man is subsequently charged over the incident.

Sources: en.wikipedia.org

Supporting material

=== Post-1918 Consorts of the Heads of the House === Hermine Reuss of Greiz (1887–1947), second wife of Wilhelm II (married 1922) Duchess Cecilie of Mecklenburg-Schwerin (1886–1954), wife of Crown Prince Wilhelm Grand Duchess Kira Kirillovna of Russia (1909–1967), wife of Prince Louis Ferdinand Princess Sophie of Isenburg (born 1978), wife of Prince Georg Friedrich

While no correlation between race and the level of neuromelanin in the substantia nigra has been reported, the significantly lower incidence of Parkinson's in blacks than in whites has "prompt[ed] some to suggest that cutaneous melanin might somehow serve to protect the neuromelanin in substantia nigra from external toxins." In addition to melanin deficiency, the molecular weight of the melanin polymer may be decreased by various factors such as oxidative stress, exposure to light, perturbation in its association with melanosomal matrix proteins, changes in pH, or in local concentrations of metal ions. A decreased molecular weight or a decrease in the degree of polymerization of ocular melanin has been proposed to turn the normally anti-oxidant polymer into a pro-oxidant. In its pro-oxidant state, melanin has been suggested to be involved in the causation and progression of macular degeneration and melanoma. Rasagiline, an important monotherapy drug in Parkinson's disease, has melanin binding properties, and melanoma tumor reducing properties. Higher eumelanin levels also can be a disadvantage, however, beyond a higher disposition toward vitamin D deficiency. Dark skin is a complicating factor in the laser removal of port-wine stains. Effective in treating white skin, in general, lasers are less successful in removing port-wine stains in people of Asian or African descent. Higher concentrations of melanin in darker-skinned individuals simply diffuse and absorb the laser radiation, inhibiting light absorption by the targeted tissue.

Although prepared to grant formal independence to Southern Rhodesia (now Rhodesia), the British government had adopted a policy of no independence before majority rule (NIBMR), dictating that colonies with a significant, politically active population of European settlers would not receive independence except under conditions of majority rule. White Rhodesians balked at the premise of NIBMR; many felt they had a right to absolute political control, at least for the time being, despite their relatively small numbers. They were also disturbed by the chaos of the post-colonial political transitions occurring in other African nations at the time, such as the Democratic Republic of the Congo. A vocal segment of the white populace was open to the concept of gradually incorporating black Rhodesians into civil society and a more integrated political structure in theory, although not without qualification and equivocation. A greater degree of social and political equality, they argued, was acceptable once more black citizens had obtained higher educational and vocational standards. The second faction in the white community was wholly unwilling to concede the principle, much less the practice, of equality to the black population. Both groups remained opposed to majority rule in the near future. However, once Rhodesia had been introduced as a topic for discussion in international bodies, extension of the status quo became a matter of concern to the British government, which perceived the scrutiny as a serious embarrassment to the United Kingdom.

Sources: en.wikipedia.org

Frequently asked questions

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Is Semax an approved medication anywhere?

It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.

What is the relationship to ACTH?

Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.

What is semax?

Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.

Network